Literature DB >> 8376686

Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators.

C R Benedict1, D H Weiner, D E Johnstone, M G Bourassa, J K Ghali, J Nicklas, P Kirlin, B Greenberg, M A Quinones, S Yusuf.   

Abstract

OBJECTIVES: The aim of this study was to determine the differences in neurohumoral responses between patients with pulmonary congestion with and without impaired left ventricular ejection fraction.
BACKGROUND: Previous studies have established the presence of neurohumoral activation in patients with congestive heart failure. It is not known whether the activation of these neurohumoral mechanisms is related to the impairment in systolic contractility.
METHODS: The 898 patients recruited into the Studies of Left Ventricular Dysfunction (SOLVD) Registry substudy were examined to identify those patients with pulmonary congestion on chest X-ray film who had either impaired (< or = 45%, group I) or preserved (> 45%, group II) left ventricular ejection fraction. Plasma norepinephrine, plasma renin activity, arginine vasopressin and atrial natriuretic peptide levels were measured in these two groups of patients and compared with values in matched control subjects.
RESULTS: Distribution of the New York Heart Association symptom classification was the same in the two groups of patients. Compared with control subjects, patients in group II with pulmonary congestion and preserved ejection fraction had no activation of the neurohumoral mechanisms, except for a small but statistically significant increase in arginine vasopressin and plasma renin activity. Compared with patients in group II, those in group I with pulmonary congestion and impaired ejection fraction had significant increases in plasma norepinephrine (p < 0.002), plasma renin activity (p < 0.02) and atrial natriuretic peptide levels (p < 0.0007). When we controlled for baseline differences between groups I and II, the between-group differences in plasma norepinephrine (p < 0.02) and atrial natriuretic peptide (p < 0.002) remained significant. However, plasma renin activity was not significantly different between groups I and II. When the effects of diuretic agents and angiotensin-converting enzyme inhibitors were adjusted, patients with lower ejection fraction were found to have significantly higher plasma norepinephrine and atrial natriuretic peptide levels.
CONCLUSIONS: The results point to the importance of the decrease in left ventricular ejection fraction as one of the mechanisms for activation of neurohormones in patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8376686     DOI: 10.1016/0735-1097(93)90480-o

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

Review 1.  Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction.

Authors:  R S McKelvie; C R Benedict; S Yusuf
Journal:  BMJ       Date:  1999-05-22

2.  Does irbesartan improve the risk of death or hospitalization for cardiovascular causes among patients with HF and PEF?

Authors:  JoAnn Lindenfeld
Journal:  Curr Cardiol Rep       Date:  2010-05       Impact factor: 2.931

Review 3.  Prevention of heart failure in the elderly: when, where and how to begin?

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

4.  Sympathetic drive stimulating diastolic dysfunction?

Authors:  Saad S Ahmad; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2017-02-09       Impact factor: 5.952

Review 5.  The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.

Authors:  John S Floras; Piotr Ponikowski
Journal:  Eur Heart J       Date:  2015-05-13       Impact factor: 29.983

6.  AlphaANP, AVP, and pituitary-thyroid axis in patients with congestive heart failure and acute respiratory failure.

Authors:  S Savastano; V Cannavale; R Valentino; A P Tommaselli; R Rossi; A Luciano; L Tauchmanovà; A Mariano; L Mazzitelli; V Macchia; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

Review 7.  Heart transplantation: approaching a new century.

Authors:  B Radovancević; O H Frazier
Journal:  Tex Heart Inst J       Date:  1999

Review 8.  Palliative care and hospice in advanced heart failure.

Authors:  Lisa Lemond; Larry A Allen
Journal:  Prog Cardiovasc Dis       Date:  2011 Sep-Oct       Impact factor: 8.194

9.  Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?

Authors:  Daniela Dobre; Mike J L DeJongste; Carolien Lucas; Ger Cleuren; Dirk J van Veldhuisen; Adelita V Ranchor; Flora Haaijer-Ruskamp
Journal:  Br J Clin Pharmacol       Date:  2006-09-12       Impact factor: 4.335

Review 10.  Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review.

Authors:  David R Buvat de Virginy
Journal:  Heart Fail Rev       Date:  2006-12       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.